PTHS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025
Revenue
15.6M
+43.1%
10.9M
+16.2%
9.4M
+26.8%
7.4M
Cost of Revenue
3.6M
+115.8%
1.7M
+0.1%
1.7M
-27.8%
2.3M
Gross Profit
12.0M
+29.9%
9.2M
+19.6%
7.7M
+51.6%
5.1M
Operating Expenses
29.3M
+31.3%
22.3M
+13.2%
19.7M
-3.6%
20.5M
R&D
600.0K
+222.6%
186.0K
-50.3%
374.0K
+157.9%
145.0K
SG&A
27.7M
+31.1%
21.1M
+14.3%
18.5M
-5.9%
19.6M
Operating Income
-17323000
-32.4%
-13088000
-9.0%
-12003000
+21.9%
-15362000
EBITDA
-16002000
-38.1%
-11588000
-7.4%
-10786000
+24.5%
-14294000
Net Income
-23417000
+6.6%
-25073000
-15.7%
-21664000
-33.4%
-16238000
EPS (Basic)
$-6.62
+12.5%
$-7.57
-11.7%
$-6.78
-27.9%
$-5.30
EPS (Diluted)
$-6.62
+12.5%
$-7.57
-11.7%
$-6.78
-27.9%
$-5.30
Shares (Diluted)
3.5M
+6.9%
3.3M
+3.6%
3.2M
+4.4%
3.1M
Pelthos Therapeutics (PTHS) โ€” Financials